In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. COVID- tests are carried out to screen for and detect infections causes by the emerging pathogen, the SARS-CoV-2- coronavirus, which was first identified in China in early 2020 GlobalData uses proprietary data and analytics to provide a comprehensive report on the covid-19 tests market in Australia. Buy the latest report here.

Smarter leaders trust GlobalData

In 2022, GlobalData’s Market Model methodology determined that the leading player in the covid-19 tests market in Australia was Abbott Laboratories followed by Altona Diagnostic, Becton Dickinson and Co, BGI Genomics, bioMerieux, DiaSorin, F. Hoffmann-La Roche, Hologic, PerkinElmer and Qiagen.

Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.

COVID-19 tests can be based on PCR, laboratory based ELISA testing or point of care rapid tests.

The covid-19 tests market in Australia can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.

For the latest analysis of the market size covid-19 tests in Australia, buy the report here.

This content was updated on 1 March 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.